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Introduction 
The dopamine (DA) hypothesis of schi-
zophrenia has gained much ground in the 
last decade. The emphasis on DA hypo-
thesis of schizophrenia is based on the abil-
ity of the DA releasing agent, amphetam-
ine, to mimic the clinical picture of para-
noid schizophrenia (Snyder 1972; Carlsson 
1978 and Crow 1982). Catecholamine pre-
cursor L - Dopa also is known to produce 
symptoms of schizophrenia (Carlsson 
1978). Although the role of DA in inducing 
schizophrenic symptoms is well accepted, 
there is so tar no direct support for a prim-
ary causative role of DA in schizophrenia. 
Studies in various laboratories have not 
provided any conclusive evidence in this 
nutter (Meltzer et al 1974, Carlsson 1978, 
Bird et d/1979, Crow 1982). 
The specific brain areas where dopami-
nergic transmission plays an important role 
are basal ganglia, limbic forebrain and tu-
bero infundibular pathway terminating in 
hypothalamus. Many of the abnormalities 
in thought process and behaviour are consi-
dered to be due to abnormalities in limbic 
forebrain (Carlsson 1978). The tubero-in-
fundibular dopaminergic pathway exerts an 
inhibitory action on prolactin release 
(Carlsson 1977, Johnstone et al 1977, Melt-
zer et al 1974, Benedetti 1984). This effect 
is mediated via the release of prolac-
tin inhibitory factor into the pituitary por-
tal vessels or through a direct action on the 
pituitary by the DA reaching the gland via 
the pituitary portal system. Thus the level 
of prolactin in blood can serve as an index 
of dopaminergic function in schizophrenia. 
In schizophrenics, neuroleptics are 
found to produce an actual normalisation of 
disturbed behaviour. All known antipsy-
chotic drugs appear to possess antidopami-
nergic activity (Crow et al 1977) and all an-
tidopaminergic agents possess antipsychot-
ic activity (Carlsson 1978). A rough corre-
lation exists between DA antagonistic ef-
fects and clinical antipsychotic potency 
(Carlsson 1978). Neuroleptics by virtue of 
their DA blockade tend to enhance secre-
tion of prolactin. Thus prolactin secretion 
also correlates well with the antipsychotic 
properties. Since both the therapeutic re-
sponse and the improvement in scrum pro-
lactin levels are caused by the antidopami-
nergic action of the neuroleptics the view 
that increased prolactin secretion can be 
used as an index of DA receptor blockade, 
has emerged. 
In the present study, it is envisaged to 
study serum prolactin levels in schizoph-
renics and control subjects to determine the 
possible correlation of dopaminergic func-
tion and schizophrenia. In addition, the pos-
sible correlation between clinical improve-
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mcnt and changes in central DA activity as 
indicated by changes in prolactin level is 
also to be observed. Very few studies have 
concentrated on prolactin levels in Indian 
patients with functional psychoses. 
Materials and Method* 
The present study included 26 patients 
(14 male and 12 female) who met Feigh-
ncr's criteria (Feighner et al 1972) for the 
diagnosis of schizophrenia and 43 control 
subjects (22 male and 21 female) matched 
for age and sex. The study was double blind. 
None of the subjects had received any 
psychoactive medication or hormonal pre-
paration for a period of at least two months 
prior to the study (none of the patients had 
received depot phenothiazines) nor was 
any one suffering from any significant phy-
sical illness. Female subjects who were 
pregnant or in pucrperium, were not inc-
luded in this study. 
Blood samples were collected from the 
patients at the time of diagnosis before be-
ing put on neuroleptics. The samples were 
collected between 9.00 and 11.00 a. m. Sc-
rum was separated and stored at -20°C un-
til the time of analysis. Samples of blood 
were again collected at the end of 3 months 
following diagnosis when all the patients 
were on maintenance medication. Serum 
prolactin was estimated by radio immu-
noassay technique (Hwang et al 1971, Ja-
cobs et a/1972). The radio immunoassay kit 
used was Hiodata Prolactin ter kit. Quanti-
tative determination by this kit is done wi-
thout any preliminary treatment of the 
samples, using prolactin labelled with
 l35I as 
the radio active tracer. 
The drugs administered were chlorpro-
mazinc (300-1200 mg.) and trifluperazine 
(15-45 mg.) The progress of the patients 
was assessed by clinical interviews, reports 
of the nurses and reports from the relatives 
of the patients. The patients were also rated 
on Brief Psychiatric Rating Scale once a 
week. None of the patients received any 
other antipsychotic drug or Electro-con-
vulsive Therapy. 
Results 
At the end of three months all the pa-
tients showed improvement as made out by 
clinical interviews, nurses' report, reports 
from the relatives and the BPRS scores. 
The prolactin levels of the control sub-
jects and those of the unmedicated schi-
zophrenics are shown in Table 1. It can be 
seen that the prolactin values do not signifi-
cantly differ in these two groups. 
Depending on the duration of the illness 
the patients were divided into two groups -
one having symptoms for less than 2 years 
and another symptomatic for more than 2 
years. The prolactin levels of the two 
groups are given in Table 2. It appears that 
these two groups differ very little as regards 
their serum prolactin levels. 
The schizophrenic subjects were also 
divided into a group exhibiting predomi-
nantly positive symptomatology (halluci-
nations, delusions, formal thought disorder, 
bizarre or disorganised behaviour) and ano-
ther exhibiting predominantly negative 
symptomatology (alogia, avolition - apa-
thy, affective flattening, anhedonia and at-
tcntional impairment). The prolactin level 
showed significant inverse correlation with 
positive symptoms, in female schizophren-
ic subjects. The unmedicated prolactin le-
vel was significantly less in female patients 
with positive symptoms when compared to 
female patients with negative symptoms. In 
male patients also there was trend in this 
direction but it .did not reach statistical 
significance. The results are presented in 
Table 3. 
The prolactin levels after medication 
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Table 1 
Prolactin level in control subjects Si schizophrenics 
CONTROLS 
SCHIZOPHRENIA 
Sex 
Male 
Female 
Male 
Female 
No. 
22 
21 
14 
12 
Age -Years 
Range 
23-41 
20-56 
26-38 
25-43 
Mean 
32 ± 1.74 
29.4 ± 2.25 
26 ± 1.43 
33.3 ±1.93 
Prolactin 
Range 
2.0- 15 
2.1-25 
2.4 - 20 
3.7 - 30 
Levels ng/ml 
Mean 
8.87 ± 1.06 
9.80 ± 1.33 
11.61 ± 1.30 
13.64 ± 2.26 
Table 2 
Correlations of duration of illness & prolactin levels 
Sex Duration of Illness  Prolactin levels 
ng/ml 
Male 6 months to 2 years 10.61 ± 1.08 
2 years and above 10.28 ± 2.29 
Fcmal* 6 months to 2 years 9.88 ± 2.09 
2 yean and above 15.71 ± 2.64 
Table 3 
Correlation of symptomatology with prolactin levels 
Sex  Nature of 
symptoms 
Prolactin levels 
ng/ml 
Mai* 6 . Negative 
8 Positive 
Fcmal* 4 Negative 
8 Positive 
1330 ± 2.19 
10.17 ± 1.80 p< 0.01 
21.25 i 2.58 
10.04 ± 2.19 
significant elevation over the baseline in all 
the patients. This rise was more marked in 
the female subjects when compared to the 
male. The results are shown in Table 4. All 
the patients had shown marked clinical im-
provement at the time of the second assay. 
Psychotic behaviour ratings showed a dec-
line in all the patients. 
Table 4 
Prolactin levels after drug therapy 
Prolactin levels ng/ml 
Sex Predrug levels Post drug levels P value 
Male 11.61 ± 1.30 34.09 ± 4.52 0.001 
Female 13.64 ± 2.26 71.44 ± 16.94 0.01 
Discussion 
In this study the baseline prolactin le-
vels in schizophrenics did not significantly 
differ from that of the control subjects. 
Hence no proof was obtained in support of 
the hypothesis that basal DA release from 
the tubero infundibular system is increased 
in schizophrenia as a part of the generalised 
hyperdopaminergic state. Other workers 
have also failed to find any significant dif-
ference between the serum prolactin levels 
of schizophrenics and controls (Cotes et al 
1978, Johnstone et al 1977, Carlsson 1977 
1978 and Grucn et al 1978): Indeed it has 
even been suggested that DA transmission 
may be reduced in some patients with 
chronic schizophrenia (Bowers 1974). This 
does not, of course, exclude the possibility 
that a disturbance of DA exists. The many 
possibilities considered in this regard are in-
creased DA released into a small brain area, 
decreased transport into the sites of meta-
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tivity, any or all of which may have escaped 
detection. It is also probable that the prim-
ary disturbance does not reside in the dopa-
minergic synapse but in a system which has 
intimate relationship with DA neurons 
(Carlsson 1977). The elevation of DA activ-
ity in a particular brain region may be due 
to an increased excitatory input or de-
creased inhibitory input. Or it may be that 
tin- dopaminergic activity is normal or even 
decreased but dopaminergic predominance ' 
exists because of a deficiency in a neuronal 
system normally serving to counterbalance 
or mitigate the dopaminergic influence 
(Carlsson 197H). 
The serum prolactin levels in all the pa-
tients showed a prominent rise after antip-
sychotic medication. As has been men-
tioned earlier the tuberoinfundibular con-
trol over prolactin release is mediated by 
dopamine. DA receptor agonists decrease 
and antagonists increase prolactin levels in 
plasma and CSF (Carlsson 1977, Bene-
dctti et al 1984, Meltzer et al 1976). The 
neuroleptic drugs by their DA receptor blo-
ckade, remove the anterior pituitary inhibi-
tion of prolactin thus enhancing the 
serum levels (Wheels et al 1980, Melt-
zer et al 1976). The antischizophrenic pro-
perty of the drug is on par with its effect on 
the scrum prolactin level. However the 
possibility that some part of the increase in 
prolactin secretion observed after neuro-
leptics may be a consequence of impovc-
ments in mental state rather than a direct 
effect of drug induced dopaminergic blo-
ckade on the tuberoinfundibular system* 
has also to be considered (Johnstone et al 
1977). 
In our study a significant inverse corre-
lation emerged between total positive 
symptoms and scrum prolactin levels. 
Earlier studies have commented on this 
pattern of hormonal response (Meltzer et al 
1976, Johnstone et al 1977). Increasing 
symptom severity and positive symptoms 
appear to be associated with increased DA 
release and decreased prolactin levels. 
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